Please assess the completion status of the following clinical trial:

Trial Title: The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~•Adult patients between the ages of 18 and 85 years (inclusive) with a diagnosis of IBS based on ROME III diagnostic criteria and meeting criteria for diagnosis of the constipation predominant subtype - IBS-C~Exclusion Criteria:~* Refusal or inability to sign informed consent for the trial~* Refusal or inability to complete daily Episodic (real-time) BM / RM calls, End of Day daily Calls, and/or complete electronic questionnaires~* BMI \> 35 or \< 18~* Women of child bearing potential who refuse to use an acceptable method of birth control for the duration of the trial~* Women who are pregnant or lactating~* Diagnosis of IBS-D or IBS-M~* Organic or obstructive disease of the small or large intestine~* Use of laxatives other than the study-supplied rescue medication (Dulcolax®, bisacodyl)~* Use of a prohibited concomitant medication within the time frame prior to screening outlined in the study protocol for that medication~* Unstable medical illness~* Bilirubin \> 3X ULN in the absence of a conjugation defect~* Any laboratory value \> 3X ULN unless discussed and approved by the study Medical Monitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 3.0 mg plecanatide (Type: ACTIVE_COMPARATOR): Plecanatide 3.0 mg dosed daily for 12 weeks
- 6.0 mg plecanatide (Type: ACTIVE_COMPARATOR): Plecanatide 6.0 mg dosed daily for 12 weeks
- Matching placebo (Type: ACTIVE_COMPARATOR): Placebo dosed daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).